

ICOAT MEDICAL´S CO-FOUNDER PROFESSOR YUJI TERAMURA WAS AWARDED THE 2025 JAPAN SOCIETY FOR ORGAN PRESERVATION AND BIOMEDICAL SCIENCES AWARD FOR THE PRE-CLINICAL RESEARCH IN THE FIELD OF TRANSPLANTATION.

iCoat Medical´s co-founder professor Yuji Teramura was awarded the 2025 Japan Society for Organ Preservation and Biomedical Sciences award for the pre-clinical research in the field of transplantation. This prestigious recognition highlights the work on cell and tissue surface engineering with iCM012, designed to attenuate immune responses, reduce ischemia reperfusion injury and improve kidney transplantation outcomes.

The award honours original and outstanding achievements that significantly contribute to organ preservation and protection of organ transplants. The results presented brought considerable attention among clinicians, also reflected in the interest raised by iCoat Medical´s recent publication in American Journal of Transplantation.

" We express pride in this award and the clinical recognition for iCM012 in transplantation" says Peder Waern, CEO of iCoat Medical.

About iCoat Medical

iCoat Medical AB is a clinical-stage pharmaceutical company developing coating-based therapeutics to mitigate and prevent ischemia–reperfusion injury in organ transplantation. Lead candidate iCM012 is designed to protect the endothelium and preserve organ function, with clinical proof-of-concept emerging from the ATMIRE study. The company is headquartered in Stockholm, Sweden.

Media & Investor Contact

Peder Waern, Chief Executive Officer

Peder.waern@icoatmedical.com

Attachments

[iCoat Medical´s co-founder professor Yuji Teramura was awarded the 2025 Japan Society for Organ Preservation and Biomedical Sciences award for the pre-clinical research in the field of transplantation.](#)